DSP-5336 targets the interaction of menin and mixed lineage leukemia proteins, which are important for various biological processes, including cell growth and genome stability.
FDA Grants Fast Track Designation to Sumitomo Pharmaceuticals’ Novel Treatment for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Leave a comment
